Long-term safety clinical trial of leptin-replacement therapy in patients with lipodystrophy after introduction of the treatment

Long-term safety clinical trial of leptin-replacement therapy in patients with lipodystrophy after introduction of the treatment - Long-term safety clinical trial of leptin in lipodystrophy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003679

Enrollment

Registered

2010-06-01

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lipodytrophy

Interventions

subcutaneous injection of human recombinant leptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of lipodusytophy 2. Treated with leptin-replacement therapy over 2 months safely and improved in metabolic abnormalities after initiation of the therapy

Exclusion criteria

Exclusion criteria: 1. Existence of complications or history which become problem for long-term leptin-replacement therapy 2. In pregnancy or nursing

Design outcomes

Primary

Measure	Time frame
adverse event, HbA1c, fasting glucose level, fasting triglyceride level, fasting insulin level	—

Countries

Japan

Contacts

Public ContactKen Ebihara

Translational Research Center, Kyoto University Hospital Department od Experimental Therapeutics

kebihara@kuhp.kyoto-u.ac.jp075-751-3173

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026